Clinical significance
Colorectal cancer is one of the most commonly diagnosed, but nothing has been approved for the chemoprevention in high-risk patients.
Polar analogs of conventional phosphodiesterase 5 inhibitors are attractive agents for colon cancer prevention because they are gut-targeted and are expected to have reduced side-effects and drug-drug interactions.